Sale

Phenylketonuria Treatment Market

Global Phenylketonuria Treatment Market Size, Trends, Growth: By Disease Type: Hyperphenylalaninemia, Mild PKU, Moderate or Variant, Classic PKU; By Product Type: Dietary Supplements, Drugs; By Route of Administration: Oral, Parenteral, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Phenylketonuria Treatment Market Outlook

The global phenylketonuria treatment market stood at a value of around USD 594.56 million in 2023. The industry is further projected to grow at a CAGR of 10% during the forecast period of 2024-2032.

 

Global Phenylketonuria Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The growing prevalence of phenylketonuria and the rising awareness regarding its treatment is driving the growth of the phenylketonuria treatment market globally. The expected increase in the production and commercialisation of new drugs would further fuel the industry growth in the coming years.

 

Properties and Applications

Phenylketonuria or PKU, is a genetic disorder due to which phenylalanine levels in blood increases. Phenylalanine is an amino acid that is derived from food and diet. The elevated phenylalanine level may cause intellectual disability and other health-related issues. Because of the excess phenylalanine in the body, children with phenylketonuria may have a musty odour. Further, patients appear to have light skin and hair colour, as well as other skin conditions like eczema.

 

Global Phenylketonuria Treatment Market By Distribution CHannel

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The global phenylketonuria treatment market can be broadly categorised based on segments like product types, route of administration, distribution channels, and regions.

  • Product Type:
    • Dietary Supplement
    • Drugs
      • Kuvan
      • Palynziq
      • CNSA-001
      • SYNB1618
  • Route of Administration:
    • Oral
    • Parenteral
  • Distribution Channel:
    • Hospital Pharmacies
    • Online Pharmacies
    • Paediatric Clinics
    • Drug Stores

The EMR report looks into the regional phenylketonuria treatment markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Phenylketonuria Treatment Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The global phenylketonuria treatment market is being driven by the growing incidence of PKU, increased R&D activities, rising health concern, enhanced diagnostics facilities, and improved health care infrastructure.

The dietary supplement segment, among other product types, accounts for a significant share in the industry owing to its increased preference among health care professionals to treat patients with phenylketonuria. The oral route remains the more preferred route of administration over parenteral due to its ease of administration and convenience. Region-wise, while North America is expected to account for the largest share in the industry, the Asia Pacific is anticipated to see the highest growth rate over the forecast period owing to the presence of increased population and the growing investment in the R&D of phenylketonuria drugs in the region.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global phenylketonuria treatment market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • BioMarin Pharmaceutical Inc.
  • Synlogic, Inc.
  • Retrophin, Inc.
  • Codexis, Inc.
  • SOM Innovation Biotech, S.A.
  • Homology Medicines, Inc.
  • Others

The EMR report gives an in-depth insight into the phenylketonuria treatment market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Product Type
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Disease Type
  • Hyperphenylalaninemia
  • Mild PKU
  • Moderate or Variant
  • Classic PKU
Breakup by Product Type
  • Dietary Supplements
  • Drugs
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Boehringer Ingelheim International GmbH
  • Eisai Co., Ltd.
  • Pfizer, Inc
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Aspen Holdings
  • Mitsubishi Tanabe Pharma Corporation.
  • Abbott Laboratories
  • GlaxoSmithKline plc.
  • Bristol-Myers Squibb Company
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Phenylketonuria Treatment Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Phenylketonuria Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Phenylketonuria Epidemiology (2016-2031)
    5.3    Europe Phenylketonuria Epidemiology (2016-2031)
    5.4    Asia-Pacific Phenylketonuria Epidemiology (2016-2031)
    5.5    Latin America Phenylketonuria Epidemiology (2016-2031)
    5.6    Middle East & Africa Phenylketonuria Epidemiology (2016-2031)
6    Phenylketonuria Treatment Market Overview 
    6.1    Phenylketonuria Treatment Market Historical Value (2017-2023) 
    6.2    Phenylketonuria Treatment Market Forecast Value (2024-2032)
7    Phenylketonuria Treatment Market Landscape
    7.1    Phenylketonuria Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Phenylketonuria Treatment: Product Landscape
        7.2.1    Analysis by Type
        7.2.2    Analysis by Technology
8    Phenylketonuria Treatment Market Dynamics
    8.1    Market Drivers and Constraints
    8.2    SWOT Analysis
    8.3    Porter’s Five Forces Model
    8.4    Key Demand Indicators 
    8.5    Key Price Indicators
    8.6    Industry Events, Initiatives, and Trends  
    8.7    Value Chain Analysis
9    Phenylketonuria Treatment Market Segmentation
    9.1    Phenylketonuria Treatment Market by Disease Type
        9.1.1    Market Overview    
        9.1.2    Hyperphenylalaninemia
        9.1.3    Mild PKU
        9.1.4    Moderate or Variant
        9.1.5    Classic PKU
    9.2    Phenylketonuria Treatment Market by Product Type
        9.2.1    Market Overview    
        9.2.2    Dietary Supplements
        9.2.3    Drugs
            9.2.3.1    Kuvan
            9.2.3.2    Playnziq 
            9.2.3.3    Others
    9.3    Phenylketonuria Treatment Market by Route of Administration
        9.3.1    Market Overview
        9.3.2    Oral
        9.3.3    Parenteral
        9.3.4    Others
    9.4    Phenylketonuria Treatment Market by Distribution Channel
        9.4.1    Market Overview
        9.4.2    Hospital Pharmacies
        9.4.3    Retail Pharmacies
        9.4.4    Online Pharmacies
        9.4.5    Others 
    9.5    Phenylketonuria Treatment Market by Region
        9.5.1    Market Overview
        9.5.2    North America
        9.5.3    Europe 
        9.5.4    Asia Pacific
        9.5.5    Latin America
        9.5.6    Middle East and Africa
10    North America Phenylketonuria Treatment Market
    10.1    Market Share by Country
    10.2    United States of America
    10.3    Canada
11    Europe Phenylketonuria Treatment Market
    11.1    Market Share by Country
    11.2    United Kingdom
    11.3    Germany
    11.4    France
    11.5    Italy
    11.6    Others
12    Asia Pacific Phenylketonuria Treatment Market
    12.1    Market Share by Country
    12.2    China
    12.3    Japan
    12.4    India
    12.5    ASEAN
    12.6    Australia
    12.7    Others
13    Latin America Phenylketonuria Treatment Market
    13.1    Market Share by Country
    13.2    Brazil
    13.3    Argentina
    13.4    Mexico
    13.5    Others
14    Middle East and Africa Phenylketonuria Treatment Market
    14.1    Market Share by Country
    14.2    Saudi Arabia
    14.3    United Arab Emirates
    14.4    Nigeria
    14.5    South Africa
    14.6    Others
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    INDIA CDSCO
        15.1.4    JAPAN PMDA
        15.1.5    Others
16    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17    Grants Analysis
    17.1    Analysis by year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization 
18    Clinical Trials Analysis
    18.1     Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19    Funding and Investment Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20    Partnership and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21    Supplier Landscape
    21.1    Boehringer Ingelheim International GmbH 
        21.1.1    Financial Analysis
        21.1.2    Product Portfolio
        21.1.3    Demographic Reach and Achievements
        21.1.4    Mergers and Acquisitions
        21.1.5    Certifications
    21.2    Eisai Co., Ltd. 
        21.2.1    Financial Analysis
        21.2.2    Product Portfolio
        21.2.3    Demographic Reach and Achievements
        21.2.4    Mergers and Acquisitions
        21.2.5    Certifications
    21.3    Pfizer, Inc 
        21.3.1    Financial Analysis
        21.3.2    Product Portfolio
        21.3.3    Demographic Reach and Achievements
        21.3.4    Mergers and Acquisitions
        21.3.5    Certifications
    21.4    Sanofi SA
        21.4.1    Financial Analysis
        21.4.2    Product Portfolio
        21.4.3    Demographic Reach and Achievements
        21.4.4    Mergers and Acquisitions
        21.4.5    Certifications
    21.5    Teva Pharmaceutical Industries Ltd. 
        21.5.1    Financial Analysis
        21.5.2    Product Portfolio
        21.5.3    Demographic Reach and Achievements
        21.5.4    Mergers and Acquisitions
        21.5.5    Certifications
    21.6    Aspen Holdings
        21.6.1    Financial Analysis
        21.6.2    Product Portfolio
        21.6.3    Demographic Reach and Achievements
        21.6.4    Mergers and Acquisitions
        21.6.5    Certifications
    21.7    Mitsubishi Tanabe Pharma Corporation. 
        21.7.1    Financial Analysis
        21.7.2    Product Portfolio
        21.7.3    Demographic Reach and Achievements
        21.7.4    Mergers and Acquisitions
        21.7.5    Certifications
    21.8    Abbott Laboratories
        21.8.1    Financial Analysis
        21.8.2    Product Portfolio
        21.8.3    Demographic Reach and Achievements
        21.8.4    Mergers and Acquisitions
        21.8.5    Certifications
    21.9    GlaxoSmithKline plc. 
        21.9.1    Financial Analysis
        21.9.2    Product Portfolio
        21.9.3    Demographic Reach and Achievements
        21.9.4    Mergers and Acquisitions
        21.9.5    Certifications
    21.10    Bristol-Myers Squibb Company
        21.10.1    Financial Analysis
        21.10.2    Product Portfolio
        21.10.3    Demographic Reach and Achievements
        21.10.4    Mergers and Acquisitions
        21.10.5    Certifications
22    Phenylketonuria Treatment - Distribution Model (Additional Insight)
    22.1    Overview 
    22.2    Potential Distributors 
    22.3    Key Parameters for Distribution Partner Assessment 
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company Competitiveness Analysis (Additional Insight)

    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global phenylketonuria treatment market reached a value of USD 594.56 million in 2023.

The market is anticipated to grow at a CAGR of 10% during the forecast period of 2024-2032 to reach a value of USD 1,401.94 billion by 2032.

The major drivers of the market include the increase in the production and commercialisation of new drugs, increased research and development activities, rising health concerns, enhanced diagnostics facilities, improved health care infrastructure, increased population, and the growing investment in the development of drugs.

Growing prevalence of phenylketonuria and the rising awareness regarding its treatment are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America,  Middle East and Africa, Europe, and  Asia Pacific with North America accounting for the largest share in the market.

Dietary supplement and drugs are the product types in the market. Drugs are further bifurcated into kuvan, palynziq, CNSA-001, and SYNB1618.

Based on route of administration, the market is divided into oral and parenteral.

The distribution channels are hospital pharmacies, online pharmacies, paediatric clinics, and drug stores.

The major players in the industry are BioMarin Pharmaceutical Inc., Synlogic, Inc., Retrophin, Inc., Codexis, Inc., SOM Innovation Biotech, S.A., and Homology Medicines, Inc., among others.

Analyst Review

The global phenylketonuria treatment market attained a value of nearly USD 594.56 million in 2023, driven by the growing prevalence of phenylketonuria. Aided increase in the production and commercialisation of new drugs and rising awareness regarding its treatment, the market is expected to witness further growth in the forecast period of 2024-2032, growing at a CAGR of 10%.

EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Dietary supplement and drugs are the product types in the market. Drugs are further bifurcated into kuvan, palynziq, CNSA-001, and SYNB1618. Based on route of administration, the market is divided into oral and parenteral. The distribution channels are hospital pharmacies, online pharmacies, paediatric clinics, and drug stores. The major regional markets for phenylketonuria treatment market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa with North America accounting for the largest share in the market. The major players in the industry are BioMarin Pharmaceutical Inc., Synlogic, Inc., Retrophin, Inc., Codexis, Inc., SOM Innovation Biotech, S.A., and Homology Medicines, Inc., among others.

EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER